Top

BMC Pregnancy and Childbirth

Published in:

Open Access 01-12-2021 | Research

Effects of half-dose and full-dose GnRH antagonists on IVF-ET outcomes: a retrospective study

Authors: Yingge Zhao, Fang Lian, Shan Xiang, Yi Yu, Conghui Pang, Yue Qiu

Published in: BMC Pregnancy and Childbirth | Issue 1/2021

Abstract

Background

Gonadotropin-releasing hormone antagonist(GnRH-ant) has been shown to have a negative effect on endometrial receptivity. Therefore, the use of lower doses of GnRH-ant during controlled ovarian stimulation (COS) may improve endometrial receptivity and clinical pregnancy rate. However, the GnRH-ant dose is relatively flexible and there is no fixed requirement for guidance. In this retrospective study, we determined the effects of half-dose and full-dose GnRH-ant on IVF-ET outcomes.

Methods

Of the 316 cycles in the 314 patients analyzed in this study, 149 received GnRH-ant half-dose (Group1), while 167 received GnRH-ant full-dose (Group2). The groups were further classified based on age and BMI. Age subgroups, were divided as age ≤ 35(subgroup A) and age > 35(subgroup B): 180 cycles in subgroup A (107 cycles in subgroup A1,73 cycles in subgroup A2), 136 cycles in subgroup B (42 cycles in subgroup B1,94 cycles in subgroupB2). The subgroups based on BMI were divided as BMI < 25 (subgroup C)and BMI ≥ 25 (subgroup D):208 cycles in subgroup C (94 cycles in subgroup C1,114 cycles in subgroup C2), 108 cycles in subgroup D (55 cycles in subgroup D1,53 cycles in subgroup D2).

Results

The number of fertilized oocytes, superior-quality embryos, clinical pregnancy rate, and live birth rate differed significantly between the two groups. However, the number of retrieved oocytes and available embryos were significantly higher in Group 1 than Group 2 (8.17 ± 4.10 vs. 7.07 ± 4.05, 2.96 ± 2.03 vs. 2.52 ± 1.62, respectively,p<0.05). Differences between the age subgroups were not statistically significant. However, in the subgroups based on BMI, the fertilized oocytes, available embryos, the number of superior-quality embryos, and the live birth rate differed significantly between the four subgroups. The number of retrieved oocytes was higher in subgroup C1 than in subgroup C2 (8.24 ± 4.04 vs. 6.83 ± 3.92,p < 0.05), In addition, the clinical pregnancy rate was slightly higher in subgroup D1 than in subgroup D2(45.45 vs. 24.53%, P < 0.05).

Conclusions

The results showed that half-dose GnRH-ant was as effective as full-dose GnRH-ant for most patients. Moreover, half-dose GnRH-ant may be more suitable in patients with BMI greater than or equal to 25. The findings of this study need to be validated in a large sample RCT.

Trial registration

Retrospectively registered.

Copperman AB, Benadiva C. Optimal usage of the GnRH antagonists: a review of the literature. Reprod Biol Endocrinol. 2013;11:20. https://doi.org/10.1186/1477-7827-11-20.CrossRefPubMedPubMedCentral

Sun Y, Xu Y, Hao G. Effect of gonadotropin releasing hormone antagonist on endometrial receptivity. Chin J Reprod Contracept. 2020;40(10):794–7.

Sun H, Yin H. Study on the first IVF / ICSI treatment of infertile patients with normal ovarian function by GnRH antagonist fixation and GnRH agonist low dose long protocol. China Matern Child Health Care. 2020;35(17):3263–6.

Zhang J, Wang S, Xu Y, Hao G. Effect of different dose antagonist regimen on ovarian reserve function in IVF/ICSI ET patients. Hebei Pharm. 2018;40(23):3530–4.

Kumbak B, Akbas H, Sahin L, Karlikaya G, Karagozoglu H, Kahraman S. Assisted reproductive treatment outcome in a large cohort of women with serum FSH above 15 IU/L. Fertil Steril. 2011;92:S255. https://doi.org/10.1016/j.fertnstert.2009.07.1653.CrossRef

Zhang A, Xu B, Sun Y, Lu X, Niu Z, Chen Q, et al. The effect of human cumulus cells on the maturation and developmental potential of immature oocytes in ICSI cycles. J Assist Reprod Genet. 2012;29:313–9. https://doi.org/10.1007/s10815-012-9712-3.CrossRefPubMedPubMedCentral

Esteves SC, Khastgir G, Shah J, Murdia K, Gupta SM, Rao DG, et al. Association between progesterone elevation on the day of human chronic gonadotropin trigger and pregnancy outcomes after fresh embryo transfer in in vitro fertilization/intracytoplasmic sperm injection cycles. Front Endocrinol. 2018;9:201. https://doi.org/10.3389/fendo.2018.00201.CrossRef

Zhang Q, He Y. Correlation between BMI and IVF fresh cycle live birth rate and its predictive value. J Clin Pathol. 2021;41(01):45–51.

Deng X, Yan H, Peng W, Duan C, Li Q, Liu Z. Retrospective analysis of the correlation between age and the timing of antagonist regimen transplantation. Jiangxi Med J. 2020;55(10):1488–91.

10.

Zhang JUANJUAN, Dong L, Zhang J, Zhao C, Ling X, Li X. Analysis of influencing factors of fresh cycle embryo transfer with antagonist regimen. Chin Matern Child Health Res. 2019;30(02):178–82.

11.

Gao Y, Mu Y, Wen H. Effect of age on the clinical effect of in vitro fertilization embryo transfer antagonist in the treatment of infertility. J Pract Med Techn. 2020;27(01):70–2.

12.

Alan B. Copperman, Claudio benadiva. Literature review on the optimal use of GnRH antagonists. J Reprod Med. 2016;25(01):93–101.

13.

Guimin Hao, Et al. The effect of antagonists on IVF embryo transfer outcome. (CNKI)2019-07-16. https://kns.cnki.net/KCMS/detail/detail.aspx?dbname=SNAD&filename=SNAD000001793006.

14.

Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23:560–79. https://doi.org/10.1093/humupd/dmx017.CrossRefPubMed

15.

Tur-Kaspa I, Ezcurra D. GnRH antagonist, Cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology. Expert Opin Drug Metab Toxicol. 2009;5:1323–36. https://doi.org/10.1517/17425250903279969.CrossRefPubMed

16.

Xu B, Wang J, Xia L, Zhang D, Wu X, Zhang A. Increased uterine NK cell numbers and perforin expression during the implantation phase in IVF cycles with GnRH antagonist protocol. Sci Rep. 2017;7:39912. https://doi.org/10.1038/srep39912.CrossRefPubMedPubMedCentral

17.

Xu B, Zhou M, Wang J, Zhang D, Guo F, Si C, et al. Increased AIF-1-mediated TNF-α expression during implantation phase in IVF cycles with GnRH antagonist protocol. Hum Reprod. 2018;33:1270–80. https://doi.org/10.1093/humrep/dey119.CrossRefPubMedPubMedCentral

18.

Friedler S, Meltzer S, Saar-Ryss B, Rabinson J, Lazer T, Liberty G. An upper limit of gonadotropin dose in patients undergoing ART should be advocated. Gynecol Endocrinol. 2016;32:965–9. https://doi.org/10.1080/09513590.2016.1199018.CrossRefPubMed

19.

Duan L, Bao S, Li K, Teng X, Hong L, Zhao X. Comparing the long-acting and short-acting forms of gonadotropin-releasing hormone agonists in the long protocol of IVF/ICSI cycles: a retrospective study. J Obstet Gynaecol Res. 2017;43:1037–42. https://doi.org/10.1111/jog.13305.CrossRefPubMed

20.

Ryan A, Wang S, Alvero R, Polotsky AJ. Prolonged gonadotropin stimulation for assisted reproductive technology cycles is associated with decreased pregnancy rates for all women except for women with polycystic ovary syndrome. J Assist Reprod Genet. 2014;31:837–42. https://doi.org/10.1007/s10815-014-0253-9.CrossRefPubMedPubMedCentral

21.

Zhang D, Xia L, Xu H, Chen Q, Jin B, Zhang A, et al. Flexible Low-Dose GnRH Antagonist Protocol Is Effective in Patients With Sufficient Ovarian Reserve in IVF. J Front Endocrinol. 2018;9:767. https://doi.org/10.3389/fendo.2018.00767.CrossRef

22.

Engel JB, Ludwig M, Junge K, Howles CM, Diedrich K. No influence of body weight on pregnancy rate in patients treated with Cetrorelix according to the single- and multiple-dose protocols. Reprod BioMed Online. 2003;6:482–7. https://doi.org/10.1016/S1472-6483(10)62171-2.CrossRefPubMed

23.

Chang YL, Hsieh YY, Tsai HD. Preliminary report on the effect of a lower dose of gonadotropin-releasing hormone antagonist (Cetrorelix) on ovarian hyperstimulation in lower-weight Asian women. Taiwan J Obstet Gynecol. 2006;45:317–20. https://doi.org/10.1016/S1028-4559(09)60250-3.CrossRefPubMed

Title: Effects of half-dose and full-dose GnRH antagonists on IVF-ET outcomes: a retrospective study
Authors: Yingge Zhao
Fang Lian
Shan Xiang
Yi Yu
Conghui Pang
Yue Qiu
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: BMC Pregnancy and Childbirth / Issue 1/2021
Electronic ISSN: 1471-2393
DOI: https://doi.org/10.1186/s12884-021-04176-8

At a glance: The STEP trials

Springer Medicine

Effects of half-dose and full-dose GnRH antagonists on IVF-ET outcomes: a retrospective study

Abstract

Background

Methods

Results

Conclusions

Trial registration

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2021

Vagus nerve stimulation ameliorates L-NAME-induced preeclampsia-like symptoms in rats through inhibition of the inflammatory response

Wireless versus routine physiologic monitoring after cesarean delivery to reduce maternal morbidity and mortality in a resource-limited setting: protocol of type 2 hybrid effectiveness-implementation study

Utilization of partograph and its associated factors among obstetric caregivers in public health institutions of Southwest Ethiopia

The prevalence and predictors of fear of childbirth among pregnant Chinese women: a hierarchical regression analysis

Reliability of maternal recall of delivery and immediate newborn care indicators in Sarlahi, Nepal

Effect of kinesio taping on low back pain during pregnancy: a systematic review and meta-analysis